Global Platelet Rich Plasma (PRP) Industry

Global Platelet Rich Plasma (PRP) Industry

  • April 2021 •
  • 384 pages •
  • Report ID: 6032540 •
  • Format: PDF
Abstract:
- Global Platelet Rich Plasma (PRP) Market to Reach $923.9 Million by 2027
- Amid the COVID-19 crisis, the global market for Platelet Rich Plasma (PRP) estimated at US$452.8 Million in the year 2020, is projected to reach a revised size of US$923.9 Million by 2027, growing at a CAGR of 10.7% over the analysis period 2020-2027. Pure Platelet Rich Plasma, one of the segments analyzed in the report, is projected to record a 10.4% CAGR and reach US$481.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Leukocyte Rich Platelet Rich Plasma segment is readjusted to a revised 11.1% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $122.3 Million, While China is Forecast to Grow at 14.1% CAGR
- The Platelet Rich Plasma (PRP) market in the U.S. is estimated at US$122.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$197.3 Million by the year 2027 trailing a CAGR of 14.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.5% and 9.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.
- Other Types Segment to Record 10.9% CAGR
- In the global Other Types segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$40.8 Million in the year 2020 will reach a projected size of US$80.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$134.2 Million by the year 2027, while Latin America will expand at a 12.4% CAGR through the analysis period.

- Select Competitors (Total 36 Featured) -
  • AdiStem Ltd.
  • Arthrex, Inc.
  • Cesca Therapeutics, Inc.
  • DePuy Synthes, Inc.
  • Dr. PRP America, LLC
  • EmCyte Corporation
  • Exactech Inc.
  • Glofinn Oy
  • Harvest Technologies Corporation
  • ISTO Biologics
  • Nuo Therapeutics
  • Stryker Corporation
  • T-Biotechnology (T-LAB)
  • Terumo BCT, Inc.
  • Zimmer Biomet